Clinical Trial Update: Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

View source ↗

Summary

Vorolanib is being studied in a second-line trial for unresectable or metastatic renal cell carcinoma, with recruitment ongoing in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Vorolanib (vorolanib)

Snippet

Sponsor: Jinling Hospital, China | Conditions: Neoplasms, Kidney Neoplasms | Status: RECRUITING